Rectal Indomethacin to Prevent Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Post-ERCP Acute Pancreatitis

In brief

The purpose of this study is to assess whether peri-procedural administration of rectal indomethacin, compared to placebo, can reduce the incidence of post-ERCP pancreatitis.

Key facts

Study ID

NCT01774604

Run by

Dartmouth-Hitchcock Medical Center

People needed

449

Starts

2013-01-01

Expected to finish

2014-12-01

Last updated by the study team

2016-11-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Scheduled for an ERCP at Dartmouth-Hitchcock
• Age greater than 18 years old
• Ability to provide written informed consent

You may not qualify if…

• Inability to provide written informed consent
• ERCP being performed for diagnosis and/or treatment of acute pancreatitis
• Current ongoing acute pancreatitis
• Previously documented allergy to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• Contra-indication to NSAID therapy (creatinine level >1.4 or active peptic ulcer disease), already taking NSAIDs (other than aspirin therapy for cardioprotection)
• Pregnant or nursing mothers

Where it is running

• Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.